Role of blinatumomab, inotuzumab, and CAR T-cells: Which to choose and how to sequence for patients with relapsed disease.
Sign Up to like & getrecommendations! Published in 2020 at "Seminars in hematology"
DOI: 10.1053/j.seminhematol.2020.11.001
Abstract: Recent approval of several novel agents has dramatically improved outcomes for patients with relapsed and refractory (R/R) B-cell acute lymphoblastic leukemia. Blinatumomab, a bi-specific T-cell engager targeted to CD3 and CD19, inotuzumab ozogamicin (InO), an… read more here.
Keywords: disease; inotuzumab; role blinatumomab; patients relapsed ... See more keywords